Therefore, we used this criterion and identified four tumors with mutations in ERCC4, one tumor with mutation in ERCC1, two tumors with mutations in FANCD2 of which one also had a mutation in ERCC4 and one sample with a mutation in SPRTN. Here, SPRTN is linked to neoplasm.